Q2 2024 EPS Estimates for DexCom, Inc. Reduced by Leerink Partnrs (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM) – Equities researchers at Leerink Partnrs decreased their Q2 2024 earnings per share (EPS) estimates for shares of DexCom in a note issued to investors on Thursday, April 25th. Leerink Partnrs analyst M. Kratky now anticipates that the medical device company will earn $0.45 per share for the quarter, down from their previous estimate of $0.47. The consensus estimate for DexCom’s current full-year earnings is $1.78 per share. Leerink Partnrs also issued estimates for DexCom’s Q2 2025 earnings at $0.55 EPS, Q4 2025 earnings at $0.73 EPS, FY2025 earnings at $2.24 EPS and FY2028 earnings at $3.74 EPS.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The company had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million.

DXCM has been the topic of several other reports. Royal Bank of Canada initiated coverage on DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective on the stock. Raymond James upped their price objective on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. Citigroup boosted their target price on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Canaccord Genuity Group increased their price target on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. Finally, UBS Group increased their price target on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $141.67.

DexCom Trading Up 1.3 %

DXCM stock opened at $127.39 on Monday. DexCom has a 1-year low of $74.75 and a 1-year high of $142.00. The firm has a market cap of $50.66 billion, a P/E ratio of 82.19, a P/E/G ratio of 2.11 and a beta of 1.20. The business’s 50 day moving average is $131.49 and its 200-day moving average is $119.53. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08.

Insider Buying and Selling at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the transaction, the chief executive officer now directly owns 333,526 shares in the company, valued at approximately $44,479,027.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the transaction, the chief executive officer now directly owns 333,526 shares in the company, valued at approximately $44,479,027.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Jon Brown sold 2,624 shares of the firm’s stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the transaction, the executive vice president now owns 68,682 shares in the company, valued at $9,618,227.28. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 189,375 shares of company stock worth $25,530,859. Insiders own 0.41% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Capital Research Global Investors boosted its position in shares of DexCom by 21.4% in the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after purchasing an additional 2,695,296 shares during the last quarter. Sands Capital Management LLC boosted its position in shares of DexCom by 10.2% in the 4th quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock worth $1,868,647,000 after purchasing an additional 1,398,136 shares during the last quarter. Capital World Investors boosted its position in shares of DexCom by 130.7% in the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after purchasing an additional 5,256,092 shares during the last quarter. Artisan Partners Limited Partnership boosted its position in shares of DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after purchasing an additional 3,672,471 shares during the last quarter. Finally, Blair William & Co. IL raised its stake in DexCom by 1.7% during the 3rd quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company’s stock worth $420,517,000 after buying an additional 73,654 shares during the period. 97.75% of the stock is currently owned by institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.